Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sikkerhed ved myeloablativ konditionering, Orca-T og allogen, donorafledt CD19/CD22-CAR (kimær antigenreceptor) T-celler hos voksne med B-celle akut lymfoblastisk leukæmi (ALL)

1. september 2026 opdateret af: Melody Smith

Fase I-forsøg, der evaluerer sikkerheden ved myeloablativ konditionering, Orca-T og allogen, donorafledt CD19/CD22-CAR (kimær antigenreceptor) T-celler hos voksne med B-celle akut lymfatisk leukæmi (ALL)

To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

22

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Palo Alto, California, Forenede Stater, 94305
        • Stanford Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Patient Inclusion Criteria:

  • Subjects in CR must have a history of chemotherapy refractory disease defined as progression or stable disease after one line of chemotherapy, or relapsed disease after achieving prior CR OR must have other high risk ALL features including: CRLF2 rearrangement, Ph-like phenotype, MLL/KMT2a rearrangement, or hypodiploid karyotype.

  • Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, PCR, FISH, or next generation sequencing) require verification of MRD in the peripheral blood or bone marrow on two occasions at least 2 weeks apart.

  • Subjects with active ALL (defined as >=5% bone marrow blasts, circulating blasts, or extramedullary disease) are eligible.

  • Age ≥ 18 and ≤ 65 years (i.e., from age 18 to < 66 years old) at the time of enrollment

  • Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2; or Karnofsky ≥ 60%

  • CD19 expression is required any time since diagnosis. CD19 expression may be detected by immunohistochemistry or by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject. In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples. Patients receiving prior CD19 CAR T cell or blinatumomab are eligible if there is no documented history of CD19 negativity on the malignant cells.

  • Subjects must have an HLA matched related donor willing to undergo unstimulated apheresis for T cell collection for CAR T cell generation followed by GCSF mobilized apheresis for HSC/Treg graft.

  • Matched related donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods

  • Subjects must have adequate organ function measured by:

    • Cardiac: Cardiac ejection fraction at rest ≥ 45%
    • Hepatic:
    • Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included where hemolysis has been excluded and with approval of the study PI)
    • ALT/AST <= 3 times ULN
    • Renal: Calculated creatinine clearance ≥ 50 mL/min or serum creatinine < 2.0 mg/dL
    • Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%
    • CNS: Subjects with CNS involvement are eligible as long as there are no overt signs or symptoms that in the evaluation of the investigator would mask or interfere with the neurological assessment of toxicity.
  • Negative serum or urine beta-HCG test in females of childbearing potential within 3 weeks of registration

  • Subjects of childbearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for twelve (12) months after receiving the preparative conditioning regimen.

  • Must be able to give informed consent. Legal authorized representative (LAR) is permitted if subject is cognitively able to provide verbal assent.

Donor Inclusion Criteria

  • Age ≥ 18 and ≤ 75 years at time of enrollment

  • Karnofsky performance status of ≥ 70% defined by institutional standards

  • Willing to donate for two separate apheresis collections (T cells and PBSC)

  • Matched related donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods

  • Negative serum or urine beta-HCG test in females of childbearing potential within 2 weeks of first apheresis

  • Seronegative for HIV-1 RNA PCR; HIV 1 and HIV 2 Ab (antibody); HTLV-1 and HTLV-2 Ab; PCR negative or sAg (surface antigen) negative for hepatitis B; negative for the Treponema pallidum antibody Syphilis screen; and negative for HIV-1 and hepatitis C by nucleic acid testing (NAT) within 40 days of donor apheresis procedures.

  • In the case that T pallidum antibody tests are positive, donors must:

    • Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history
    • Have completed effective antibiotic therapy to treat syphilis
    • Have a documented negative non-treponemal test (such as RPR) or in the case of a positive non-treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease

Patient Exclusion Criteria:

  • History of other malignancy unless disease free for at least 3 years. At the discretion of the Principal Investigator, subjects in remission for 1-2 years prior to enrollment may be deemed eligible after considering the nature of other malignancy, likelihood of recurrence for one year following therapy, and impact of prior treatment on risk of CD19/CD22-CAR T cells and Treg graft. Subjects in remission <1 year are not eligible. The following exceptions apply:

    • Nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) is eligible.
    • Hormonal therapy in subjects in remission >1 year will be allowed.
  • Patients who have undergone a prior allogeneic or autologous stem cell transplant.

  • Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:

    • a positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or
    • the presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) >1000 by solid phase immunoassay
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.

  • Known history of infection with any of the following:

  • HIV

  • Hepatitis B (HBsAg positive) **

  • Hepatitis C virus (anti HCV positive) **

    ** A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.

  • Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.

  • Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy), peri-transplant anti-thymocyte globulin (ATG), or alemtuzumab. For patients that have previously been exposed to a T cell-depleting agent, a 5-half-life washout of the agent must occur prior to planned Transplant Day 0.

  • Hyperleukocytosis (≥ 50,000 blasts/μL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy.

  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.

  • Pregnant or breast feeding

  • Patients with known autoimmune disease requiring the use of systemic immunosuppressive therapy within the last year

  • Presence of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement that in the judgment of the investigator may impair the ability to evaluate neurotoxicity.

  • Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment

Donor Exclusion Criteria

  • Evidence of active infection

  • Seropositive for HIV-1 or -2, HTLV-1 or -2

  • Positive PCR test results indicating acute or chronic HBV infection. Patients with isolated HBV core antibody positivity will not be excluded. Donors whose HBV infection status cannot be determined conclusively by serologic test results (www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation.

  • Potential for Zika virus infection as defined as any of the following:

    • Medical diagnosis of Zika virus infection in the past 6 months
    • Residence in, or travel to, an area with active Zika virus transmission within the past 6 months.
    • Unprotected sex within the past 6 months with a person who is known to have either of the risk factors listed above (donor exclusion criterion 5.a or 5.b)
  • Donors determined to be ineligible based on the results of Zika virus screening may be determined to be eligible if:

    o The donor has no signs or symptoms consistent with active Zika virus infection and

    o Either of the following is true: i. The donor is a first-degree or second-degree blood relative of the recipient ii. Urgent medical need, meaning no comparable human cell product is available and the recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the Investigator.

  • Pregnant or breastfeeding female

  • Medical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Dose escalation

Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells

CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration

Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Patients Who Received Donor CD19/CD22-CAR T Cells
Tidsramme: 42 days

Will be measured by the ability to manufacture donor CD19/CD22-CAR T cells that meet established release specifications

42 days
Assessment of the Donors Safety CD19/CD22-CAR T Cells Plus the Orca-T Graft
Tidsramme: 42 days

Safety of the donor CD19/CD22-CAR T cells plus the Orca-T graft will be assessed by the incidence of engraftment without Grade III to IV acute GVHD

42 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative Incidence of Disease Progression
Tidsramme: 1 year

Measure by the cumulative incidence of relapse or progression of disease as well as non-relapse mortality (NRM) following donor CD19/CD22-CAR T cells plus Orca-T infusion

1 year
Frequency of Secondary Graft Failure
Tidsramme: 1 year

Assessment of the rate of secondary graft failure following donor CD19/CD22-CAR T cells plus Orca-T infusion

1 year
Progression-free Survival
Tidsramme: 1 year

progression-free survival following a donor CD19/CD22-CAR T cell infusion plus Orca-T infusion

1 year
Overall Survival
Tidsramme: 1 year

overall survival following a donor CD19/CD22-CAR T cell infusion plus Orca-T infusion

1 year
Infectious Disease Complication
Tidsramme: 1 year

Evaluate the incidence of greater than Grade 3 infectious disease complications

1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Lori Muffly, MD, Stanford University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

18. august 2022

Primær færdiggørelse (Faktiske)

18. juni 2025

Studieafslutning (Anslået)

1. december 2045

Datoer for studieregistrering

Først indsendt

17. august 2022

Først indsendt, der opfyldte QC-kriterier

17. august 2022

Først opslået (Faktiske)

19. august 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner